These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30488510)

  • 21. [Acceptability of vaccination against human papillomavirus (HPV) by pediatricians, mothers and young women in Ho Chi Minh City, Vietnam].
    Phan DP; Pham QT; Strobel M; Tran DS; Tran TL; Buisson Y
    Rev Epidemiol Sante Publique; 2012 Dec; 60(6):437-46. PubMed ID: 23137871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance Database.
    Héquet D; Pouget N; Estevez JP; Robain M; Rouzier R
    Bull Cancer; 2015 Nov; 102(11):892-7. PubMed ID: 26526386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
    Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
    JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact.
    Gilca V; Salmerón-Castro J; Sauvageau C; Ogilvie G; Landry M; Naus M; Lazcano-Ponce E
    Vaccine; 2018 Aug; 36(32 Pt A):4800-4805. PubMed ID: 29887322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months.
    Lazcano-Ponce E; Stanley M; Muñoz N; Torres L; Cruz-Valdez A; Salmerón J; Rojas R; Herrero R; Hernández-Ávila M
    Vaccine; 2014 Feb; 32(6):725-32. PubMed ID: 24355090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of thyroiditis risk associated with HPV vaccination among girls aged 9-18 years: A time-varying cohort study.
    Castillo-Cano B; Martín-Pérez M; Llorente-García A; Montero-Corominas D; Comas-Cufí M; Martín-Merino E
    Vaccine; 2022 Aug; 40(33):4816-4826. PubMed ID: 35792023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
    Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
    Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
    Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
    Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human Papillomavirus Vaccination in Washington State: Estimated Coverage and Missed Opportunities, 2006-2013.
    Oltean HN; Lofy KH; Goldoft MJ; DeBolt CA
    Public Health Rep; 2016; 131(3):474-82. PubMed ID: 27252567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Vaccine and Cervical Cancer Screen project 2 (VACCS 2): Linking cervical cancer screening to a two-dose HPV vaccination schedule in the South-West District of Tshwane, Gauteng, South Africa.
    Snyman LC; Dreyer G; Visser C; Botha MH; van der Merwe FH
    S Afr Med J; 2015 Mar; 105(3):191-4. PubMed ID: 26294825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Chesson HW; Curtis CR; Gee J; Bocchini JA; Unger ER;
    MMWR Recomm Rep; 2014 Aug; 63(RR-05):1-30. PubMed ID: 25167164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human Papillomavirus Vaccine - Knowledge and Attitudes among Parents of Children Aged 10-14 Years: a Cross-sectional Study, Tîrgu Mureş, Romania.
    Voidăzan S; Tarcea M; Morariu SH; Grigore A; Dobreanu M
    Cent Eur J Public Health; 2016 Mar; 24(1):29-38. PubMed ID: 27070967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
    Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
    Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increasing human papillomavirus vaccine acceptability by tailoring messages to young adult women's perceived barriers.
    Gerend MA; Shepherd MA; Lustria ML
    Sex Transm Dis; 2013 May; 40(5):401-5. PubMed ID: 23588130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Base de Datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP): A data resource for pharmacoepidemiology in Spain.
    Maciá-Martínez MA; Gil M; Huerta C; Martín-Merino E; Álvarez A; Bryant V; Montero D;
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1236-1245. PubMed ID: 32337840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
    Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [HPV vaccination: active offer in an Italian region].
    Terracciano E; D'Alò GL; Aquilani S; Aversa AM; Bartolomei G; Calenda MG; Catapano R; Compagno S; Della Rovere P; Fraioli A; Ieraci R; Reggiani D; Sgricia S; Spadea A; Zaratti L; Franco E
    Ig Sanita Pubbl; 2017; 73(1):77-94. PubMed ID: 28428646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.